Bronchopulmonary Dysplasia Drug Therapy

Award Information
Agency:
Department of Health and Human Services
Branch
n/a
Amount:
$163,329.00
Award Year:
2003
Program:
SBIR
Phase:
Phase I
Contract:
1R43HL072614-01
Award Id:
65743
Agency Tracking Number:
HL072614
Solicitation Year:
n/a
Solicitation Topic Code:
n/a
Solicitation Number:
n/a
Small Business Information
SYNTRIX BIOSYSTEMS, INC., BOX 166, 16625 REDMOND WAY NE, STE M, REDMOND, WA, 98052
Hubzone Owned:
N
Minority Owned:
N
Woman Owned:
N
Duns:
n/a
Principal Investigator:
DEANMAEDA
(425) 867-9692
DMAEDA@SYNTRIXBIO.COM
Business Contact:
JOHNZEBALA
(425) 867-9692
jzebala@syntrixbio.com
Research Institute:
n/a
Abstract
DESCRIPTION (provided by applicant): Neutrophils are bloodborne inflammatory cells that exhibit potent oxidative and phagocytic activities. One important component of the neutrophils' role in the immune system is its ability to migrate rapidly towards sites of inflammation in a process known as chemotaxis. Chemotaxis is mediated through numerous chemotactic factors that include IL-8 and Gro-alpha interacting with the neutrophil receptors CXCR1 and CXCR2. Improper and heightened neutrophil recruitment is a hallmark of several inflammatory diseases that include bronchopulmonary dysplasia in neonates subjected to mechanical ventilation with supplemental oxygen. We are developing a potent series of novel and proprietary chemotaxis inhibitors known as the nicotinamide thioglycolate esters to treat bronchopulmonary dysplasia. While initial screening identified several nicotinamide thioglycolate esters that potently inhibited chemotaxis (IC50 < 40 nM), their mechanism of inhibition is enigmatic. To further advance this promising therapeutic class, additional research is required to define their exact mechanism of action. This Phase I/II Fast-Track proposal is aimed at defining the pharmacology and pharmaceutics of these novel chemotaxis inhibitors. In Phase I, we aim to identify whether the site of action is at CXCR1 and/or CXCR2, or less likely, at the natural ligand Gro-alpha. We then aim to show that the site of action is either intracellular or extracellular. Defining the mechanism of inhibition in Phase I will establish the feasibility of proceeding to Phase II, where we aim to precisely identify the site of action at the molecular level, define and optimize their pharmaceutics, and establish efficacy in an animal model of bronchopulmonary dysplasia. The market for these therapeutic compounds is estimated to be $50 million annually in the U.S.

* information listed above is at the time of submission.

Agency Micro-sites


SBA logo

Department of Agriculture logo

Department of Commerce logo

Department of Defense logo

Department of Education logo

Department of Energy logo

Department of Health and Human Services logo

Department of Homeland Security logo

Department of Transportation logo

Enviromental Protection Agency logo

National Aeronautics and Space Administration logo

National Science Foundation logo
US Flag An Official Website of the United States Government